Switzerland · Delayed Price · Currency is CHF Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of CHF 223.47 billion. The enterprise value is 255.98 billion.
| Market Cap | 223.47B |
| Enterprise Value | 255.98B |
Important Dates
The next confirmed earnings date is Tuesday, July 21, 2026.
| Earnings Date | Jul 21, 2026 |
| Ex-Dividend Date | Mar 10, 2026 |
Share Statistics
Novartis AG has 1.83 billion shares outstanding. The number of shares has decreased by -3.80% in one year.
| Current Share Class | 1.83B |
| Shares Outstanding | 1.83B |
| Shares Change (YoY) | -3.80% |
| Shares Change (QoQ) | -0.67% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 39.23% |
| Float | 1.74B |
Valuation Ratios
The trailing PE ratio is 21.80 and the forward PE ratio is 17.19. Novartis AG's PEG ratio is 2.04.
| PE Ratio | 21.80 |
| Forward PE | 17.19 |
| PS Ratio | 4.92 |
| PB Ratio | 7.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.89 |
| P/OCF Ratio | 14.53 |
| PEG Ratio | 2.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.76, with an EV/FCF ratio of 18.20.
| EV / Earnings | 23.58 |
| EV / Sales | 5.64 |
| EV / EBITDA | 13.76 |
| EV / EBIT | 17.33 |
| EV / FCF | 18.20 |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 1.21.
| Current Ratio | 0.85 |
| Quick Ratio | 0.53 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | 2.03 |
| Debt / FCF | 2.68 |
| Interest Coverage | 15.14 |
Financial Efficiency
Return on equity (ROE) is 34.93% and return on invested capital (ROIC) is 21.10%.
| Return on Equity (ROE) | 34.93% |
| Return on Assets (ROA) | 10.54% |
| Return on Invested Capital (ROIC) | 21.10% |
| Return on Capital Employed (ROCE) | 21.14% |
| Weighted Average Cost of Capital (WACC) | 6.25% |
| Revenue Per Employee | 602,951 |
| Profits Per Employee | 144,232 |
| Employee Count | 75,267 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, Novartis AG has paid 1.82 billion in taxes.
| Income Tax | 1.82B |
| Effective Tax Rate | 14.38% |
Stock Price Statistics
The stock price has increased by +25.86% in the last 52 weeks. The beta is 0.49, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +25.86% |
| 50-Day Moving Average | 117.56 |
| 200-Day Moving Average | 111.85 |
| Relative Strength Index (RSI) | 63.57 |
| Average Volume (20 Days) | 2,704,900 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of CHF 45.38 billion and earned 10.86 billion in profits. Earnings per share was 5.60.
| Revenue | 45.38B |
| Gross Profit | 34.29B |
| Operating Income | 14.78B |
| Pretax Income | 12.66B |
| Net Income | 10.86B |
| EBITDA | 18.39B |
| EBIT | 14.78B |
| Earnings Per Share (EPS) | 5.60 |
Balance Sheet
The company has 5.53 billion in cash and 37.70 billion in debt, with a net cash position of -32.17 billion or -17.57 per share.
| Cash & Cash Equivalents | 5.53B |
| Total Debt | 37.70B |
| Net Cash | -32.17B |
| Net Cash Per Share | -17.57 |
| Equity (Book Value) | 31.22B |
| Book Value Per Share | 16.19 |
| Working Capital | -3.82B |
Cash Flow
In the last 12 months, operating cash flow was 15.38 billion and capital expenditures -1.32 billion, giving a free cash flow of 14.07 billion.
| Operating Cash Flow | 15.38B |
| Capital Expenditures | -1.32B |
| Depreciation & Amortization | 3.59B |
| Net Borrowing | 11.58B |
| Free Cash Flow | 14.07B |
| FCF Per Share | 7.68 |
Margins
Gross margin is 75.55%, with operating and profit margins of 32.56% and 23.92%.
| Gross Margin | 75.55% |
| Operating Margin | 32.56% |
| Pretax Margin | 27.90% |
| Profit Margin | 23.92% |
| EBITDA Margin | 40.51% |
| EBIT Margin | 32.56% |
| FCF Margin | 30.99% |
Dividends & Yields
This stock pays an annual dividend of 3.70, which amounts to a dividend yield of 3.03%.
| Dividend Per Share | 3.70 |
| Dividend Yield | 3.03% |
| Dividend Growth (YoY) | 5.71% |
| Years of Dividend Growth | 29 |
| Payout Ratio | 64.15% |
| Buyback Yield | 3.80% |
| Shareholder Yield | 6.83% |
| Earnings Yield | 4.86% |
| FCF Yield | 6.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novartis AG is 123.43, which is 1.24% higher than the current price. The consensus rating is "Hold".
| Price Target | 123.43 |
| Price Target Difference | 1.24% |
| Analyst Consensus | Hold |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 4.22% |
| EPS Growth Forecast (3Y) | 6.16% |
Stock Splits
The last stock split was on May 7, 2001. It was a forward split with a ratio of 40.
| Last Split Date | May 7, 2001 |
| Split Type | Forward |
| Split Ratio | 40 |
Scores
Novartis AG has an Altman Z-Score of 3.27 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.27 |
| Piotroski F-Score | 5 |